Following the memorandum of understanding, MyEG will begin applying for regulatory approvals and certifications for the breath test to be made commercially available in the country. MyEG will also be appointed as Breathonix’s exclusive distribution partner to undertake the commercial sale and marketing of its technology in the country.
The breath test was developed in October 2020, achieving over 90% accuracy in a clinical trial involving 180 patients. It also detected the virus with a 95% specificity, which means it could identify those without the disease in 95 out of 100 cases.
According to MyEG, the test can be administered by any trained personnel, even non medically trained professionals.
“The game-changing breathalyzer test has underdone clinical trials at three locations, in particular Singapore and Dubai, conducted from June 2020 to April 2021 and has received provisional authorisation from Singapore’s Health Sciences Authority.
“Breathonix is also working with Singapore’s Ministry of Health for a deployment trial at Tuas Checkpoint, where incoming travelers will be screened alongside the current compulsory antigen rapid test,” said MyEG.
“The impending launch of the breath test is the latest addition to a growing range of Covid-19 related innovations that MyEG has introduced since the outbreak of the pandemic, which includes deep-throat saliva test kits, the MySafeTravel screening and quarantine arrangement system for travellers and the MySafeQ quarantine hotel accommodation programme for low-risk domestic Covid-19 patients, among others,” it added.
The breathalyzer test has undergone clinical trials at three locations, including Singapore and Dubai, from June 2020 to April 2021. It has also received provisional authorization from Singapore’s Health Sciences Authority.
Breathonix is currently working with Singapore’s Ministry of Health for a deployment trial at Tuas Checkpoint, where incoming travelers will be screened using the rapid breath test system alongside the current compulsory antigen rapid test.